Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

1.250 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Revelation Biosciences (REVB) Stock Is Down 38%
Revelation Biosciences shares are trading lower by 38% during Tuesday's session. The company agreed to a $4M warrant exercise, closing December 3. 
Via Benzinga
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
From Revelation Biosciences, Inc.
Via Business Wire
Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results
 
Via Benzinga
Gold Down Over 1%; US Initial Jobless Claims Increase
 
Via Benzinga
Dow Jumps 100 Points; BJ's Wholesale Earnings Top Estimates
 
Via Benzinga
Topics Stocks
Why Wolfspeed Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
From Revelation Biosciences Inc.
Via Business Wire
US Stocks Higher; Target Posts Upbeat Earnings
 
Via Benzinga
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024
REVB stock results show that Revelation Biosciences missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met its primary endpoint and identified a maximum tolerated dose. 
Via Benzinga
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
REVB stock results show that Revelation Biosciences missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.